Chicago / Edinburgh
United States · Nasdaq

Aktis Oncology

Aktis Oncology develops experimental cancer treatments using engineered miniproteins designed to deliver radioactive medicine to tumors.

Aktis Oncology (Ticker: AKTS US) develops experimental cancer treatments using engineered miniproteins designed to carry radioactive medicine to tumors. Its platform uses proteins designed to deliver Actinium-225, an alpha-emitting radioactive material, to selected targets; its design goals include tumor penetration and rapid clearance from the body. Its lead candidate, [225Ac]Ac-AKY-1189, targets Nectin-4 and is being tested in a Phase 1b clinical trial. The company intended to use proceeds to advance its lead program and move a second candidate targeting B7-H3 into clinical trials. Eli Lilly made a $100.00 million cornerstone investment before the offering was increased.

The scheduled listing date on Nasdaq was January 9, 2026. The proposed offering comprises 17,700,000 shares at an indicative price range of $16.00–18.00 per share. At the indicative range midpoint, the base offering would represent $300.90 million in gross proceeds, excluding any unexercised over-allotment.

J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen acted as underwriters.

Prepared with IPOX® AI assistance. Information may contain errors.

Prepared with IPOX® AI assistance. Information may contain errors.

THE IPOX® NEWSLETTERS

Stay ahead of the next listing.

Research and insight from the global new listings market.

Explore our newsletters